RAKOVINA
THERAPEUTICS INC.

Disclaimer / 免责声明

Certain forward-looking statements contained herein constitute "forward-looking information" (collectively, "forward-looking information") within the meaning of applicable Canadian securities laws. The words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking information. Forward-looking information reflects the Company's beliefs and assumptions based on information available at the time the information was stated and, as such, is not a guarantee of future performance. Such statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance, or achievements that may be expressed or implied by such forward-looking statements.

In making the forward-looking statements included in this presentation, we have made various material assumptions, including but not limited to: the Company being able to obtain financing on acceptable terms; additional sources of funding, including grants and funding from partners; the Company's ability to attract and retain skilled staff; future research and development plans for the Company proceeding substantially as currently envisioned; the Company's ability to identify a product candidate; the Company's ability to obtain positive results from the Company's research and development activities, including pre-clinical and clinical trials; the Company's ability to secure patents for its product candidates; the Company's ability to protect patents and proprietary rights; COVID-19 or future pandemic or acts of God on the operations and long-term strategic priorities of the Company. Although the Company believes these assumptions are reasonable in the circumstances, actual results may differ materially from the expectations set out in the forward-looking information. Given these risks, readers are cautioned not to place undue reliance on forward-looking information in this presentation. Furthermore, unless otherwise stated, the forward-looking information contained in this presentation are made as of the date of this presentation, and the Company has no intention and undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law.

Leading precision oncology company focused on DNA-damage response inhibitors (DDRi) / 专注于DNA损伤反应抑制剂(DDRi)的领先精准肿瘤学公司

Lead pre-clinical candidate kt-3283, a novel dual-function DDRi; under development for pediatric and adult solid tumors and expected in clinic H1' 2024 / **领先的临床前候选药物kt-3283，一种新型双功能DDRi**； 正在开发治疗儿童和成人实体瘤，预计将于2024年上半年进入临床

Robust pipeline of novel DDRi-based therapeutics; including kt-3000 series dual-function DDRi; kt-2000 series PARPi; and kt-4000 series alkylating-DDRi / **基于DDRi的新型疗法的强大管线**；包括kt-3000系列双功能DDRi； kt-2000系列PARPi； 和kt-4000系列烷基化-DDRi



Powerful drug discovery and lead optimization platform established in collaboration with **The University of British Columbia** / 与**卑诗大学**合作建立**强大的药物发现和先导化合物优化平台**

Significant partnering opportunities with Big Pharma investing more than **$25 billion in DDRi technologies** to date / 与大型制药公司的**重大合作机会**， 迄今为止在**DDRi技术**上投资超过**$250亿**

>12 months working capital to support research and development operations at end of June, 2023 / 截至2023年6月底，**有超过12个月的运营资金**来支持研发业务

RAKOVINA THERAPEUTICS INC.

Experienced team proven in drug discovery and development
有丰富药物发现和开发经验的团队

Management Team / 管理层

JEFFREY BACHA, BSC, MBA / 理学学士、工商管理硕士

Executive Chairman/Director / 执行董事会主席/董事

KPMG · DelMar Pharmaceuticals · Sernova Corp

DAVID HYMAN, CPA / 注册会计师

Chief Financial Officer / 首席财务官

Deloitte. · Raymond James · Camcor

MADS DAUGAARD, PHD / 博士

President & Chief Scientific Officer / 总裁兼首席科学官

UBC · Var2 Pharma

NEIL SANKAR, MD / 医学博士

Executive Medical Director / 执行医疗总监

Genentech · abbvie

JOHN LANGLANDS, PHD / 博士

Chief Operating Officer / 首席运营官

KINTARA Therapeutics · inflazyme pharmaceuticals

Scientific Advisors / 科学顾问

DENNIS BROWN, PHD / 博士

Chair, Scientific Advisory Board (SAB)/Director: / 科学顾问委员会 (SAB) 主席/董事：

KINTARA Therapeutics · ChemGenex Pharmaceuticals · Matrix Pharmaceutical, Inc.

LEONARD POST, PHD / 博士

SAB/Senior Drug Development Advisor / 科学顾问委员会/高级药物开发顾问

LEAD Therapeutics · BIOMARIN

WANG SHEN, PHD / 博士

SAB/Senior Medicinal Chemistry Advisor / 科学顾问委员会/高级药物化学顾问

Abbott · AMGEN · sunesis

RAKOVINA THERAPEUTICS INC.

Focused on DNA-damage response – a major driver of many cancers / 专注于 DNA 损伤反应——许多癌症的主要驱动因素



RAKOVINA THERAPEUTICS INC.

BRCA-mutant cancers / BRCA 突变癌症

- Four FDA-approved PARP-inhibitors / 四种 FDA 批准的PARP 抑制剂
- ~$3 billion annual sales / 年销售额约 $30亿

DDR Deficiency / DDR 缺陷

- 74.9% of solid tumors / 74.9%的实体瘤

nature REVIEWS CLINICAL ONCOLOGY

Targeting BRCA-deficient cancers using poly(ADP-ribose) polymerase (PARP) inhibitors is the archetype of synthetic lethality / 使用聚（ADP-核糖）聚合酶（PARP）抑制剂靶向 BRCA基因缺陷癌症是合成致死的原型

Preclinical and clinical research with PARP inhibition has revealed multiple resistance mechanisms across a variety of cancer subtypes / PARP抑制剂的临床前和临床研究揭示了多种癌症亚型的多重耐药机制

The therapeutic landscape of DDR inhibitors is rapidly expanding (beyond *BRCA* mutations) to include inhibitors of other key mediators of DNA repair and replication / DDR抑制剂的治疗范围正在迅速扩大（超越*BRCA*突变），包括DNA修复和复制的其他关键介质的抑制剂

Big Pharma has invested more than $25 billion in DDRi technologies
大型制药公司已在DDRi技术上投资超过$250亿

	Biotech / 生物科技	Pharma / 药企	Deal Size / 交易规模	Year / 年份	Type / 类型	Development Stage / 开发阶段
ACQUISITION OF FIRST GENERATION PARP-i / 收购第一代PARP-i	KuDOS PHARMACEUTICALS	AstraZeneca	$210M / $2.1亿	2005	Acq / 收购	preclinical / 临床前
	MEDIVATION	Pfizer	$14.0B / $140亿	2016	Acq. / 收购	Phase 3 / 三期
	TESARO	gsk	$5.1B / $51亿	2019	Acq. / 收购	FDA Approved / FDA批准
PRE-CLINICAL DEALS FOR NEXT-GENERATION DDR-i / 为下一代DDR-i进行的临床前交易	REPARE THERAPEUTICS	Bristol Myers Squibb	$3.0B / $30亿	2020	Invest. / 投资	Pre-clinical collaboration / 临床前合作
	IDEAYA BIOSCIENCES	gsk	$3.0B / $30亿	2020	Invest. / 投资	Pre-clinical collaboration / 临床前合作
	artios DNA DAMAGE RESPONSE	NOVARTIS	$1.3B / $13亿	2021	Invest. / 投资	Pre-clinical collaboration / 临床前合作

Powerful Drug Discovery and Lead Optimization Platform
强大的药物发现和先导化合物优化平台

Lead optimization infrastructure established in collaboration with The University of British Columbia / 与卑诗大学合作建立先导化合物优化基础设施



Phase 1-2 Clinical Trials / 1-2 期临床试验

Pivotal Clinical Trials / 关键临床试验

RAKOVINA THERAPEUTICS INC.

Robust pipeline of novel DNA-damage response inhibitors (DDRi)
强大的新型 DNA 损伤反应抑制剂 (DDRi) 管线

		Key Differentiator 关键差异化因素	Indication 适应症	Lead Optimization 先导化合物优化	Pre-clinical / IND enabling 临床前/ IND 启动	Phase 1/2 1/2期	Pivotal 关键	Upcoming Milestones / 即将到来的里程碑
Pre-clinical 临床前	**kt-3000** Dual-function HDAC+PARP inhibition 双功能HDAC+PARP抑制剂	• Active against PARPi-resistant and HR-proficient tumors / 对PARPi耐药和 HR 正常肿瘤具有活性	Childhood and adult solid tumors / 儿童和成人实体瘤					Initiate Phase 1-2 clinical trials in H1'2024 / 2024 年上半年启动1-2期临床试验
Lead Optimization 先导化合物优化	**kt-2000** PARP1-selective inhibitors PARP1选择性抑制剂	• Improved side-effect profile / 改善副作用 • Improved CNS penetration / 改善中枢神经系统渗透性	BRCA-positive tumors with brain metastases / BRCA阳性伴脑转移肿瘤					Pre-clinical lead selection; IND-enabling studies in 2024 / 临床前先导化合物选择；2024年启动IND研究
	kt-4000 DNA-alkylating PARP-inhibitor / DNA 烷基化PARP抑制剂	• Improved efficacy through synergistic effects / 通过协同效应提高疗效	Solid Tumors / 实体瘤					*In vivo* proof-of-concept / *体内*概念验证

RAKOVINA THERAPEUTICS INC.

Lead Candidate
Dual Function DDRi kt-3283
先导候选双功能DDRi kt-3283

RAKOVINA
THERAPEUTICS INC.

kt-3283: novel dual function DNA-damage response inhibitor
kt-3283：新型双功能DNA损伤反应抑制剂

Oral inhibitor of PARP and HDAC to treat cancers resistant to FDA-approved PARP-inhibitors / 口服PARP和HDAC抑制剂，用于治疗对FDA批准的PARP抑制剂耐药的癌症

PARP is a cellular enzyme involved in repair of single-strand DNA breaks / PARP是一种参与修复单链DNA断裂的细胞酶

HDACs are proteins involved in DNA folding and cellular replication / HDAC是参与DNA折叠和细胞复制的蛋白质

FDA-approved PARP-inhibitors (PARPi) have become mainstay treatment in BRCA-mutated cancers / FDA 批准的PARP抑制剂 (PARPi) 已成为BRCA突变癌症的主要疗法

FDA-approved HDAC inhibitors (HDACi) are important in the treatment of blood-cancers, but use in solid tumors has been limited due to toxicity / FDA 批准的HDAC抑制剂 (HDACi)在治疗血癌中很重要，但由于毒性而在实体瘤中的应用受限

Compelling rationale for PARPi + HDACi combination therapy to overcome resistance to PARPi / PARPi + HDACi 联合疗法克服PARPi耐药的令人信服的理由

Clinical utility of this approach has been limited due to toxicity / 由于毒性，该方法的临床实用性受限

kt-3283 differentiation driven by: / kt-3283 的差异化驱动因素：

- **Enhanced chemical properties (potency & selectivity) / 增强的化学特性（功效和选择性）**
- **Activity against treatment-resistant phenotypes / 对抗治疗耐药表型的活性**
- **Observed synergy of dual function vs. single-agent treatments / 与单一疗法相比，观察到了双功能的协同作用**

RAKOVINA THERAPEUTICS INC.

kt-3283: Overcoming PARPi treatment resistance
kt-3283：克服PARPi治疗的耐药性

HR-deficient tumor / HR缺陷肿瘤



PARP-inhibitor therapy / PARP抑制剂治疗

Tumor shrinks / 肿瘤缩小



BRCA-gene regains function / BRCA基因恢复功能

Treatment-resistance & aggressive tumor regrowth / 治疗耐药性和侵袭性肿瘤再生

kt-3283 dual function DDRi / kt-3283双功能DDRi

(1) HDAC-inhibition degrades BRCA-gene protein / HDAC抑制降解BRCA基因蛋白

(2) PARP-inhibition prevents DNA repair / PARP抑制防止DNA修复

Tumor Re-sensitized to treatment / 肿瘤对治疗重新敏感



HR-proficient tumor / HR正常肿瘤



PARP-inhibitor therapy / PARP抑制剂治疗

Continued tumor growth / 肿瘤持续生长

No effect / 无效果



kt-3283 dual function DDRi / kt-3283双功能DDRi

(1) HDAC-inhibition degrades BRCA-gene protein / HDAC抑制降解BRCA基因蛋白

(2) PARP-inhibition prevents DNA repair / PARP抑制防止DNA修复

Tumor responsive to treatment / 肿瘤对治疗有反应



RAKOVINA THERAPEUTICS INC.

kt-3283: Overcoming PARPi treatment resistance
kt-3283：克服 PARPi 治疗耐药性

HR-deficient tumor (BRCA-mut) /
HR缺陷肿瘤（BRCA突变）

kt-3283



Lynparza olaparib



kt-3283 is ***10x more potent*** than FDA-approved PARPi Lynparza (olaparib) against **HR-deficient** tumor cells / 对比 FDA 批准的 PARPi Lynparza (olaparib)，kt-3283 对抗**HR缺陷**肿瘤细胞的*功效超过10倍*

HR-proficient tumor (BRCA-wt) /
HR正常肿瘤 (BRCA野生型)

kt-3283



Lynparza olaparib



kt-3283 exhibits ***potent anti-cancer activity*** against **HR-proficient, PARPi-resistant** tumors / kt-3283 对**HR正常、PARPi耐药**肿瘤表现出*有效的抗癌活性*

RAKOVINA THERAPEUTICS INC.

kt-3283: Overcoming PARPi treatment resistance
kt-3283：克服 PARPi 治疗耐药性

	Untreated control / 未经治疗的对照组	*kt-3283*	Lynparza® olaparib	Zolinza® (vorinostat) capsules
Potency / 功效 EC_{50} *(µmol/L)*		**0.166**	**4.69**	**1.53**



RAKOVINA THERAPEUTICS INC.

kt-3283: Achieving synergy to treat resistant cancers
kt-3283：实现耐药性癌症的协同治疗

untreated Control (DMSO) / 未治疗的对照组(DMSO)



Lynparza olaparib



Zolinza (vorinostat) capsules



Lynparza olaparib + Zolinza (vorinostat) capsules



kt-3283



AACR SPECIAL CONFERENCE: SARCOMAS
May 9 - 12, 2022
Doubletree by Hilton Montreal
Montreal, QC, Canada

kt-3283 dual function DDRi is highly effective against PARPi resistant cancer cells and achieves a synergistic effect superior to the combination of FDA-approved PARPi (Lynparza®) and HDACi (Zolinza®) at equimolar treatment doses. / kt-3283双功能DDRi对PARPi耐药癌细胞高度有效，并在等摩尔治疗剂量下实现优于FDA批准的PARPi (Lynparza®)和HDACi (Zolinza®)联合用药的协同作用。

Affect on Ewing sarcoma cancer cells (cell cycle arrest) / 对尤文肉瘤癌细胞的影响（细胞周期停滞）

Treatment / 治疗	G0/G1	S	G2/M	conclusion / 结论
untreated (DMSO) / 未治疗（DMSO）	60.1	16.6	23	
kt-3283	12.5	**35.8**	**49.1**	**Highly effective / 非常有效**
Lynparza olaparib	54.9	17	27.1	No effect (resistant) / 无影响（耐药）
Zolinza (vorinostat) capsules	50.4	17.7	31.5	Moderately active / 适度活跃
Lynparza + Zolinza	42.5	15.5	41.1	Moderately active / 适度活跃

RAKOVINA THERAPEUTICS INC.

DDRi Pipeline
DDRi管线

RAKOVINA
THERAPEUTICS INC.

kt-2000 series: Potential best-in-class PARPi
kt-2000 系列：潜在的同类最佳PARPi

Oral PARP-inhibitors designed for reduced side-effects and improved CNS penetration
口服 **PARP**抑制剂，旨在减少副作用并提高中枢神经系统渗透性

FDA-approved PARPi harbor hematologic toxicity and poor brain penetration /
FDA 批准的PARPi存在血液毒性和脑渗透性差

kt-2000 series drug candidates have demonstrated compelling anti-tumor activity in animal models / kt-2000系列候选药物在动物模型中表现出引人注目的抗肿瘤活性

kt-2000 series differentiation driven by: / kt-2000 系列的差异化驱动因素：

- **PARP-1 v. PARP-2 selectivity / PARP-1与PARP-2 选择性**
- **Improved CNS penetration / 改善中枢神经系统渗透性**



Triple Negative Orthotopic Breast Cancer Model (MDA-MB-436) / 三阴性原位乳腺癌模型(MDA-MB-436)



Tumor size & weight kt-2125 vs. untreated control (day 29) / 与未治疗的对照组相比，kt-2125治疗后的肿瘤大小和重量（第 29 天）

Vehicle ➔
空白对照
kt2125 ➔



RAKOVINA THERAPEUTICS INC.

kt-4000 series: DNA-alkylating PARPi
kt-4000 系列：DNA 烷基化PARPi

Oral PARP-inhibitors designed expand utility of PARPi beyond HR-deficient tumors
口服PARP抑制剂，将PARPi的效用扩展到HR缺陷肿瘤之外

FDA-approved PARPi activity limited to cancers with underlying HR-defect / FDA 批准的PARPi活性仅限于具有潜在HR缺陷的癌症

kt-4000 series drug candidates are rationally designed treat cancers not normally responsive to PARPi / kt-4000系列候选药物经过合理设计，可治疗通常对PARPi无反应的癌症

kt-4000 series differentiation driven by: / kt-4000 系列的差异化驱动因素：

- **DNA-alkylation function combined with potent inhibition of DNA-repair function / DNA烷基化功能与 DNA修复功能的有效抑制相结合**



- ✓ **kt-4000 drug candidates alkylate DNA in a similar manner as temozolomide, an FDA-approved DNA alkylating agent / kt-4000候选药物烷基化DNA的方式与美国FDA批准的DNA烷基化药物替莫唑胺相似**
- ✓ **kt-4000 drug candidates demonstrate dose-dependent anti-cancer activity against PARPi-resistant cancers *in vitro* / kt-4000候选药物在*体外*对PARPi耐药性癌症具有剂量依赖性抗癌活性**



RAKOVINA THERAPEUTICS INC.

Highlights and Milestones
亮点和里程碑

RAKOVINA
THERAPEUTICS INC.

Financial Highlights / 财务亮点

$1.5M / $150 万

est. working capital / 预计营运资金

as at 30-Jun 2023 / 截至2023年6月30日

~12 months / 约12个月

research funding / 研究经费

expected runway with cash on hand / 手头现金预计用途

69.8M / 6980万

basic & fully diluted shares outstanding / 基本与完全摊薄后的发行在外股份

shares outstanding 30-Jun 2023 / 截止2023 年6月30日发行在外股份

>45%

insider held / 内部人士持股

per yahoo finance / 来源于雅虎财经

RAKOVINA THERAPEUTICS INC.

Recent progress and upcoming milestones
近期进展和即将到来的里程碑



Rakovina Therapeutics: Summary of key differentiators
Rakovina Therapeutics：主要差异化因素总结：

Lead kt-3283 dual function DDRi / 领先kt-3283双功能DDRi

- Differentiated to overcome PARPi resistance / 克服 PARPi耐药性的差异化
- Targeted to enter human trials H1’24 / 目标是在24年上半年进入人体试验

Pipeline / 管线

- Portfolio of novel DNA-damage response inhibitor technologies / 新型DNA损伤反应抑制剂技术组合



Platform / 平台

- Robust drug discovery and lead optimization infrastructure / 强大的药物发现和先导化合物优化基础设施

Balance sheet / 资产负债表

- Funded for multiple value-creating milestones / 为多个创造价值的里程碑提供资金

RAKOVINA THERAPEUTICS INC.

Contact / 联系方式

Corporate

公司

Rakovina Therapeutics Inc.
Vancouver, British Columbia
Canada V6E 1T7
(403) 613-1453
www.rakovinatherapeutics.com

Media & Investor Relations

媒体与投资者关系

Frontier Merchant Capital Group
(647) 771-1711
sharon@frontiermcg.com

ir@rakovinatherapeutics.com

Auditor / 审计

Davidson & Company